Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T58921
(Former ID: TTDS00338)
|
|||||
Target Name |
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
|
|||||
Synonyms |
PPAR-gamma; Nuclear receptor subfamily 1 group C member 3; NR1C3
|
|||||
Gene Name |
PPARG
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Acute diabete complication [ICD-11: 5A2Y] | |||||
2 | Alzheimer disease [ICD-11: 8A20] | |||||
3 | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Function |
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).
Click to Show/Hide
|
|||||
BioChemical Class |
Nuclear hormone receptor
|
|||||
UniProt ID | ||||||
Sequence |
MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSF
DIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKT QLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNC RIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLR ALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQE QSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLAS LMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVII LSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQL LQVIKKTETDMSLHPLLQEIYKDLY Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
ADReCS ID | BADD_A02556 ; BADD_A04820 ; BADD_A05675 | |||||
HIT2.0 ID | T58J2Y |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 5 Approved Drugs | + | ||||
1 | Lobeglitazone | Drug Info | Approved | Type-2 diabetes | [2] | |
2 | Pioglitazone | Drug Info | Approved | Diabetic complication | [3], [4] | |
3 | Rosiglitazone XR | Drug Info | Approved | Type-2 diabetes | [5] | |
4 | Thiazolidinedione | Drug Info | Approved | Alzheimer disease | [6] | |
5 | Troglitazone | Drug Info | Approved | Diabetic complication | [7], [8] | |
Clinical Trial Drug(s) | [+] 25 Clinical Trial Drugs | + | ||||
1 | Balaglitazone | Drug Info | Phase 3 | Type-1 diabetes | [9] | |
2 | CS-038 | Drug Info | Phase 3 | Type-2 diabetes | [10] | |
3 | FARGLITAZAR | Drug Info | Phase 3 | Type-1 diabetes | [11], [12] | |
4 | Imiglitazar | Drug Info | Phase 3 | Type-2 diabetes | [13], [14] | |
5 | Ragaglitazar | Drug Info | Phase 3 | Type-1 diabetes | [15], [16] | |
6 | Rivoglitazone | Drug Info | Phase 3 | Ocular inflammation | [17] | |
7 | Rosiglitazone + metformin | Drug Info | Phase 3 | Diabetic complication | [18] | |
8 | Rosiglitazone + simvastatin | Drug Info | Phase 3 | Type-2 diabetes | [19] | |
9 | TESAGLITAZAR | Drug Info | Phase 3 | Type-1 diabetes | [20] | |
10 | ZYH-1 | Drug Info | Phase 3 | Lipid metabolism disorder | [21] | |
11 | MBX-102 | Drug Info | Phase 2/3 | Gout | [22] | |
12 | CHS-131 | Drug Info | Phase 2 | Multiple sclerosis | [23] | |
13 | FK-614 | Drug Info | Phase 2 | Type-2 diabetes | [24] | |
14 | GED-0507-34-Levo | Drug Info | Phase 2 | Inflammatory bowel disease | [25] | |
15 | MBX-2044 | Drug Info | Phase 2 | Type-2 diabetes | [26] | |
16 | Naveglitazar | Drug Info | Phase 2 | Diabetic complication | [27] | |
17 | Netoglitazone | Drug Info | Phase 2 | Non-alcoholic fatty liver disease | [28], [29] | |
18 | OMS405 | Drug Info | Phase 2 | Nicotine dependence | [30] | |
19 | ONO-5129 | Drug Info | Phase 2 | Diabetic complication | [31] | |
20 | T3D-959 | Drug Info | Phase 1/2 | Alzheimer disease | [32] | |
21 | CLX-0921 | Drug Info | Phase 1 | Type-2 diabetes | [33] | |
22 | DSP-8658 | Drug Info | Phase 1 | Type-2 diabetes | [34] | |
23 | Englitazone sodium | Drug Info | Phase 1 | Type-2 diabetes | [35] | |
24 | GW-409544 | Drug Info | Phase 1 | Hyperlipidaemia | [36], [37] | |
25 | Oxeglitazar | Drug Info | Phase 1 | Gout | [38] | |
Discontinued Drug(s) | [+] 18 Discontinued Drugs | + | ||||
1 | AVE-0847 | Drug Info | Discontinued in Phase 2 | Hyperlipidaemia | [39] | |
2 | GSK-677954 | Drug Info | Discontinued in Phase 2 | Non-alcoholic fatty liver disease | [29] | |
3 | Indeglitazar | Drug Info | Discontinued in Phase 2 | Type-2 diabetes | [40] | |
4 | KRP-297 | Drug Info | Discontinued in Phase 2 | Type-2 diabetes | [41] | |
5 | Reglixane | Drug Info | Discontinued in Phase 2 | Diabetic complication | [42] | |
6 | Sodelglitazar | Drug Info | Discontinued in Phase 2 | Hyperlipidaemia | [43] | |
7 | YM-440 | Drug Info | Discontinued in Phase 2 | Type-1 diabetes | [44] | |
8 | DS-6930 | Drug Info | Discontinued in Phase 1 | Diabetic complication | [45] | |
9 | E-3030 | Drug Info | Discontinued in Phase 1 | Hyperlipidaemia | [46] | |
10 | LY-929 | Drug Info | Discontinued in Phase 1 | Lipid metabolism disorder | [47], [48] | |
11 | AD-5075 | Drug Info | Terminated | Type-2 diabetes | [51], [52] | |
12 | AKP-320 | Drug Info | Terminated | Type-2 diabetes | [53] | |
13 | BVT-142 | Drug Info | Terminated | Type-2 diabetes | [54] | |
14 | CS-204 | Drug Info | Terminated | Metabolic disorder | [55] | |
15 | DARGLITAZONE | Drug Info | Terminated | Diabetic complication | [56] | |
16 | Edaglitazone | Drug Info | Terminated | Type-2 diabetes | [57] | |
17 | SB-219994 | Drug Info | Terminated | Diabetic complication | [58], [59] | |
18 | Sipoglitazar | Drug Info | Terminated | Diabetic complication | [60] | |
Preclinical Drug(s) | [+] 2 Preclinical Drugs | + | ||||
1 | Ciglitazone | Drug Info | Preclinical | Pulmonary fibrosis | [49] | |
2 | MC-3002 | Drug Info | Preclinical | Metabolic disorder | [50] | |
Mode of Action | [+] 4 Modes of Action | + | ||||
Agonist | [+] 51 Agonist drugs | + | ||||
1 | Lobeglitazone | Drug Info | [2] | |||
2 | Pioglitazone | Drug Info | [1], [61] | |||
3 | Rosiglitazone XR | Drug Info | [62] | |||
4 | Thiazolidinedione | Drug Info | [1] | |||
5 | Troglitazone | Drug Info | [1], [63], [64] | |||
6 | Glitazone | Drug Info | [65] | |||
7 | Rivoglitazone | Drug Info | [74] | |||
8 | Rosiglitazone + metformin | Drug Info | [62] | |||
9 | Rosiglitazone + simvastatin | Drug Info | [62] | |||
10 | MBX-102 | Drug Info | [26] | |||
11 | FK-614 | Drug Info | [24] | |||
12 | GED-0507-34-Levo | Drug Info | [76] | |||
13 | MBX-2044 | Drug Info | [26] | |||
14 | OMS405 | Drug Info | [79] | |||
15 | CLX-0921 | Drug Info | [33] | |||
16 | Englitazone sodium | Drug Info | [35], [83] | |||
17 | 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 | Drug Info | [84] | |||
18 | 3-phenyl acrylic acid derivative 1 | Drug Info | [84] | |||
19 | A-substituted phenylpropionic acid derivative 1 | Drug Info | [84] | |||
20 | A-substituted phenylpropionic acid derivative 2 | Drug Info | [84] | |||
21 | Biaromatic compound 1 | Drug Info | [84] | |||
22 | Crystalline anhydrous toluene derivative 1 | Drug Info | [84] | |||
23 | Flavonoid derivative 8 | Drug Info | [84] | |||
24 | Fused aromatic compound 1 | Drug Info | [84] | |||
25 | Fused ring compound 1 | Drug Info | [84] | |||
26 | MRL20 | Drug Info | [84] | |||
27 | MRL24 | Drug Info | [84] | |||
28 | Phenylpropionic acid derivative 1 | Drug Info | [84] | |||
29 | Phenylpyridine derivative 3 | Drug Info | [84] | |||
30 | PMID25416646-Compound-Figure2-J | Drug Info | [84] | |||
31 | PMID25416646-Compound-Figure2-K | Drug Info | [84] | |||
32 | PMID25416646-Compound-Figure2-N | Drug Info | [84] | |||
33 | PMID25416646-Compound-Figure5-A | Drug Info | [84] | |||
34 | PMID25416646-Compound-Figure5-C | Drug Info | [84] | |||
35 | PMID25416646-Compound-Figure5-E | Drug Info | [84] | |||
36 | PMID25416646-Compound-Figure5-H | Drug Info | [84] | |||
37 | Spirolaxine derivative 1 | Drug Info | [84] | |||
38 | Sulfonamide derivative 18 | Drug Info | [84] | |||
39 | Thiazolidine dione crystalline derivative 1 | Drug Info | [84] | |||
40 | GSK-677954 | Drug Info | [29] | |||
41 | Indeglitazar | Drug Info | [86] | |||
42 | Sodelglitazar | Drug Info | [88] | |||
43 | LY-929 | Drug Info | [92] | |||
44 | Ciglitazone | Drug Info | [93] | |||
45 | BVT-142 | Drug Info | [54], [95] | |||
46 | CS-204 | Drug Info | [96] | |||
47 | DARGLITAZONE | Drug Info | [97], [83] | |||
48 | SB-219994 | Drug Info | [98] | |||
49 | 15-deoxy-Delta(12, 14)-prostaglandin J(2) | Drug Info | [63] | |||
50 | DB-900 | Drug Info | [100] | |||
51 | GW7845 | Drug Info | [102] | |||
Modulator | [+] 28 Modulator drugs | + | ||||
1 | Balaglitazone | Drug Info | [66] | |||
2 | CS-038 | Drug Info | [67], [68] | |||
3 | FARGLITAZAR | Drug Info | [69], [70] | |||
4 | Imiglitazar | Drug Info | [71], [72] | |||
5 | MURAGLITAZAR | Drug Info | [73] | |||
6 | Ragaglitazar | Drug Info | [16] | |||
7 | TESAGLITAZAR | Drug Info | [75] | |||
8 | ZYH-1 | Drug Info | [60] | |||
9 | CHS-131 | Drug Info | [23] | |||
10 | Naveglitazar | Drug Info | [77] | |||
11 | Netoglitazone | Drug Info | [78] | |||
12 | ONO-5129 | Drug Info | [80] | |||
13 | T3D-959 | Drug Info | [81] | |||
14 | DSP-8658 | Drug Info | [82] | |||
15 | GW-409544 | Drug Info | [37] | |||
16 | Oxeglitazar | Drug Info | [38] | |||
17 | AVE-0847 | Drug Info | [85] | |||
18 | KRP-297 | Drug Info | [87] | |||
19 | Reglixane | Drug Info | [80] | |||
20 | DS-6930 | Drug Info | [90] | |||
21 | E-3030 | Drug Info | [91] | |||
22 | MC-3002 | Drug Info | [80] | |||
23 | AD-5075 | Drug Info | [52] | |||
24 | AKP-320 | Drug Info | [94] | |||
25 | Edaglitazone | Drug Info | [57] | |||
26 | Sipoglitazar | Drug Info | [60] | |||
27 | GW-2331 | Drug Info | [101] | |||
28 | ZY H2 | Drug Info | [103] | |||
Ligand | [+] 1 Ligand drugs | + | ||||
1 | Cannabinoid quinone derivative 1 | Drug Info | [84] | |||
Inhibitor | [+] 8 Inhibitor drugs | + | ||||
1 | YM-440 | Drug Info | [89], [83] | |||
2 | (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid | Drug Info | [99] | |||
3 | (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid | Drug Info | [99] | |||
4 | (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid | Drug Info | [99] | |||
5 | (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid | Drug Info | [99] | |||
6 | 2-chloro-5-nitro-N-phenylbenzamide | Drug Info | [99] | |||
7 | 3-(5-methoxy-1H-indol-3-yl)propanoic acid | Drug Info | [99] | |||
8 | 9-hydroxyoctadecadienoic acid | Drug Info | [99] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. | |||||
REF 2 | Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. | |||||
REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2694). | |||||
REF 4 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||||
REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 6 | Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther. 2000 Autumn;2(3):429-40. | |||||
REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2693). | |||||
REF 8 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 9 | ClinicalTrials.gov (NCT00515632) Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy. U.S. National Institutes of Health. | |||||
REF 10 | ClinicalTrials.gov (NCT02173457) Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients. U.S. National Institutes of Health. | |||||
REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2672). | |||||
REF 12 | Clinical pipeline report, company report or official report of MacroGenics. | |||||
REF 13 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2675). | |||||
REF 14 | Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. Open Med Chem J. 2011;5(Suppl 2):93-8. | |||||
REF 15 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2664). | |||||
REF 16 | Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. | |||||
REF 17 | ClinicalTrials.gov (NCT00571519) Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||||
REF 18 | ClinicalTrials.gov (NCT00499707) Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects. U.S. National Institutes of Health. | |||||
REF 19 | Clinical pipeline report, company report or official report of GlaxoSmithKline. | |||||
REF 20 | ClinicalTrials.gov (NCT00229710) GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes. U.S. National Institutes of Health. | |||||
REF 21 | A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 g compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014 Feb;16(2):63-71. | |||||
REF 22 | ClinicalTrials.gov (NCT00353587) Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin. U.S. National Institutes of Health. | |||||
REF 23 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 24 | FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8. | |||||
REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032997) | |||||
REF 26 | MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. | |||||
REF 27 | ClinicalTrials.gov (NCT00065312) An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes. U.S. National Institutes of Health. | |||||
REF 28 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2707). | |||||
REF 29 | Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. | |||||
REF 30 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035962) | |||||
REF 31 | ClinicalTrials.gov (NCT00335712) Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||||
REF 32 | ClinicalTrials.gov (NCT02560753) Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease. | |||||
REF 33 | A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8. | |||||
REF 34 | ClinicalTrials.gov (NCT01042106) Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults. U.S. National Institutes of Health. | |||||
REF 35 | PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61. | |||||
REF 36 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3440). | |||||
REF 37 | Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. | |||||
REF 38 | Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. | |||||
REF 39 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020608) | |||||
REF 40 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022483) | |||||
REF 41 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010490) | |||||
REF 42 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008953) | |||||
REF 43 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018093) | |||||
REF 44 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010082) | |||||
REF 45 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558) | |||||
REF 46 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021476) | |||||
REF 47 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2657). | |||||
REF 48 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014823) | |||||
REF 49 | Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. | |||||
REF 50 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021065) | |||||
REF 51 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2701). | |||||
REF 52 | Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95. | |||||
REF 53 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022081) | |||||
REF 54 | A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. | |||||
REF 55 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026847) | |||||
REF 56 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003002) | |||||
REF 57 | A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 2002;7(5):343-6. | |||||
REF 58 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2698). | |||||
REF 59 | Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998 Feb;284(2):751-9. | |||||
REF 60 | Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. | |||||
REF 61 | Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. | |||||
REF 62 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||||
REF 63 | Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. | |||||
REF 64 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||||
REF 65 | Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. | |||||
REF 66 | Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97. | |||||
REF 67 | Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. | |||||
REF 68 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.Br J Pharmacol.2006 Jul;148(5):610-8. | |||||
REF 69 | Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84. | |||||
REF 70 | Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res. 2005 Nov;54(11):464-70. | |||||
REF 71 | A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. | |||||
REF 72 | A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits. Atherosclerosis. 2005 Jan;178(1):1-7. | |||||
REF 73 | Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95. | |||||
REF 74 | A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13. | |||||
REF 75 | Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32. | |||||
REF 76 | PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7. | |||||
REF 77 | The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61. | |||||
REF 78 | Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84. | |||||
REF 79 | Clinical pipeline report, company report or official report of Avarx. | |||||
REF 80 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 81 | Phrma report (2013 Alzheimers disease) | |||||
REF 82 | Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9. | |||||
REF 83 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 84 | PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. | |||||
REF 85 | DOI: 10.1038/scibx.2012.669 | |||||
REF 86 | Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. | |||||
REF 87 | KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6. | |||||
REF 88 | Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7. | |||||
REF 89 | The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci. 2006 Aug;101(4):311-7. | |||||
REF 90 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558) | |||||
REF 91 | Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8. | |||||
REF 92 | CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection. | |||||
REF 93 | New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. | |||||
REF 94 | Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato) oxovanadium(IV) in ZDF rats. Canadian Journal of Physiology and Pharmacology. 12/2003; 81(11):1049-55. | |||||
REF 95 | US patent application no. 7,816,328, Substituted fused heterocyclic c-glycosides. | |||||
REF 96 | Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137. | |||||
REF 97 | The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab. 2010 February; 30(2): 352-360. | |||||
REF 98 | PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J. 2004 Jul;24(1):18-23. | |||||
REF 99 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 100 | CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof. | |||||
REF 101 | PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71. | |||||
REF 102 | A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999 Nov 15;59(22):5671-3. | |||||
REF 103 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.